HIV Prevention

Resource Center

Interactive Features

prevention

08/10/2022

Recently, the USPSTF published recommendations for pre-exposure prophylaxis use in high-risk individuals. But would you prescribe PrEP to women are at risk for HIV exposure as well? Let us know by taking...

08/10/2022

poll

USPSTF Recommendations on HIV

06/29/2022

The USPSTF released recommendations about HIV screening and PrEP use. What impact do you think the recommendations will have?

06/29/2022

pre-exposure prophylaxis

Pop Quiz: Oral vs Injectable PrEP

05/27/2022

Do you know which patient populations should be prescribed injectable vs oral pre-exposure prophylaxis? Take our pop quiz to find out!

05/27/2022

Pop quiz

Testing Patients Taking PrEP

03/29/2022

All patients taking pre-exposure prophylaxis for HIV should be tested regularly. Which is the preferred testing method for individuals starting or restarting PrEP for HIV?

03/29/2022

prevention

Poll: On-Demand PrEP

03/21/2019

Is on-demand pre-exposure prophylaxis effective in preventing HIV? Let us know what you think by taking our poll.

03/21/2019

HIV

Quiz: Developing an HIV Vaccine

12/20/2018

Listen to our podcast with Dr Shane Crotty about the HIV vaccine his team is creating. Then, see if you know the answer to this question about how the vaccine is being developed.

12/20/2018

Screening

Quiz: HIV Screening and Diagnosis

05/21/2018

For more infectious diseases content, visit the Resource Center

Pre-exposure prophylaxis (PrEP) is a preventive medication administered intravenously or orally to reduce the risk of human immunodeficiency virus (HIV) infection that may occur following sex or injection drug use.

For more infectious diseases content, visit the Resource Center

Any licensed health care provider can prescribe PrEP. Among clinicians who are most likely to prescribe PrEP are:

primary care providers; internal medicine specialists; infectious disease specialists

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had a partner with HIV

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had sex without consistently using a condom

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- have been diagnosed with a sexually transmitted disease in the past 6 months

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who inject drugs, have an injection partner with HIV, or share needles, syringes, or other drug injection equipment

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who have previously been prescribed PrEP, have reported continued risky behavior, or previously used multiple courses of PrEP

For more infectious diseases content, visit the Resource Center

The HIV Risk Incidence Index for Men Who Have Sex With Men (HIRI-MSM) and Injection Drug Users Risk Index (IDU) are often used to stratify risk in patients.

For more infectious diseases content, visit the Resource Center

PrEP may reduce HIV transmission from sex by 99% when taken as prescribed.

For more infectious diseases content, visit the Resource Center

The use of PrEP among recommended users increased from 3% in 2015 to 25% in 2020.

For more infectious diseases content, visit the Resource Center

Sources:

For more infectious diseases content, visit the Resource Center

HIV Prevention Snapshot

Reviewed by Daniel Erias, MD and Jeffrey Kwong, DNP, MPH, AGPCNP-BC

Research Summaries

research summary

research summary

Directly Observed Therapy Accurately Measures PrEP Adherence

09/26/2023

Leigh Precopio

Pre-exposure prophylaxis (PrEP) adherence continues to be one of the main challenges for the elimination of HIV transmission. Researchers tested the use of an automated directly observed therapy...

09/26/2023

research summary

research summary

Text Message Intervention Supports PrEP Adherence Among Some At-Risk Populations

08/28/2023

Leigh Precopio

In a recent study, researchers examined the effectiveness of text messaging to support the use of pre-exposure prophylaxis use in certain patient populations who are at high-risk of HIV infection.

08/28/2023

research summary

Individuals Seeking Mpox Vaccination Are Also at Increased Risk of STIs, HIV

04/27/2023

Leigh Precopio

Researchers aimed to determine the risk profile of individuals without HIV who were seeking vaccination against mpox and if these patients would benefit from HIV pre-exposure prophylaxis use.

04/27/2023

CONFERENCE CONVERAGE

Urine Test Shows Predictive Values for PrEP Adherence

04/24/2023

Researchers determined the predictive value of urine point-of-care tenofovir antibody test and compared the results against self-reported PrEP use and TFV-diphosphate levels in dried blood spots. Their...

04/24/2023

Conference Coverage

TDF/FTC Considered Safe Among Pregnant Women Per Objective TFV-DP Levels

03/20/2023

Researchers compared pre-exposure prophylaxis (PrEP) use with birth outcomes using objective levels of tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) of women during the second or third trimester...

03/20/2023

September 2024

Current Issue

September 2024

Volume 64

Issue 9